Background: Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide, with early detection and accurate monitoring of tumor burden being critical for improving patient outcomes. Existing biomarkers such as alpha-fetoprotein (AFP) have limited sensitivity and specificity, underscoring the need for more reliable diagnostic and prognostic tools. Study Design: In this retrospective cohort study, we developed the Hepatocellular Carcinoma Beta Methylation Value (HBMV) using two targeted CpG amplicon panels, HBMV-6 and HBMV-28. HBMV values were calculated by summing beta methylation values across predefined loci and validated using The Cancer Genome Atlas, 15 Gene Expression Omnibus datasets comprising more than 1,400 liver tissue samples, and a prospective plasma cohort including 18 patients with HCC and 4 non cancer controls. Diagnostic, prognostic, and longitudinal performance was compared with AFP. Results: Both HBMV panels accurately distinguished HCC from non-cancer liver tissue, achieving area under the receiver operating characteristic curve values greater than 0.9 in tissue and greater than 0.8 in plasma. Across independent tissue cohorts, HBMV-28 values increased stepwise from normal liver to cirrhosis, dysplasia, and HCC. Higher HBMV values were associated with larger tumor size and worse overall survival. In longitudinal plasma analyses, HBMV decreased after surgical resection or transplantation and increased during disease progression, effectively distinguishing progression from non-progression with an area under the curve up to 0.87. In contrast, AFP demonstrated modest sensitivity and failed to reliably track treatment response. Conclusions: HBMV is a sensitive and biologically grounded biomarker for HCC diagnosis, prognosis, and real time disease monitoring. These findings support further prospective evaluation of HBMV as a noninvasive tool for clinical surveillance and treatment response assessment.
Javanshir et al. (Fri,) studied this question.